UBS Reaffirms Buy on Linde (LIN) at $500, Sees 10%+ EPS Growth

Linde plc (NASDAQ:LIN) is one of the best hydrogen stocks to buy right now. On December 12, UBS reaffirmed a Buy rating on Linde plc (NASDAQ:LIN) and maintained a price target of $500. UBS based its decision on Linde’s Q3 2025 earnings and its outlook. The firm said it expects Linde’s EPS to grow over 10% in the coming year based on 4-6% growth from management actions and another 4-6% from capital allocation. This calculation excludes any benefits from macro growth.

With 1-2% growth in industrial production, UBS indicated that Linde’s EPS growth could rise into the low-to-mid teens. The firm also expects a strong upside for Linde’s stock in the foreseeable future for several reasons including benefits from project ramp-ups, backlog execution, and efficient capital deployment. There is also potential for additional volume growth in two-thirds of the portfolio if industrial production improves modestly.

Earlier on December 12, Mizuho lowered its price target for Linde to $495 from $520 and maintained an Outperform rating on the shares. The change was due to “lower market and peer multiples” and not related to any company-specific issues. Mizuho highlighted that Linde’s project backlog has stayed stable recently and is expected to grow by the end of 2026. But as Linde continues to focus on high-potential areas such as clean energy projects, electronics, and commercial space launches, Mizuho stated, there is massive growth potential for the stock.

Linde plc (NASDAQ:LIN) is a global industrial gases and engineering company. The company operates the largest liquid hydrogen capacity and distribution system in the world. Its main products are green hydrogen produced through electrolysis, hydrogen refueling solutions, and advanced technologies for hydrogen storage and transportation.

While we acknowledge the potential of LIN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Affordable AI Stocks to Buy Now and 15 Best Biotech Stocks to Buy According to Wall Street Analysts.

Disclosure: None. This article is originally published at Insider Monkey.